Loading...

Home
ETF
09688

09688

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

09688 News

<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)

Mar 03 2026aastocks

M Stanley Predicts WUXI BIO (02269.HK) Share Price Increase in Next 45 Days, Raises Target Price to $50

Feb 12 2026aastocks

Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Jan 05 2026Businesswire

Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia

Dec 23 2025Businesswire

UBS Maintains Buy Rating on ZAI LAB, Lowers Target Price to HKD 20.1

Dec 22 2025aastocks

Zai Lab Updates Three Medicines in China's National Reimbursement Drug List

Dec 07 2025Newsfilter

<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)

Nov 18 2025aastocks

BofAS Reduces ZAI LAB (09688.HK) Price Target to $19.92 Due to Sales Challenges for Core Products

Nov 10 2025aastocks

Citi Lowers ZAI LAB (09688.HK) Price Target to US$58 Following Disappointing 3Q Revenue Results

Nov 10 2025aastocks

ZAI LAB Falls 8% to Over One-Year Low Following Disappointing 3Q Results

Nov 07 2025aastocks

<M Stanley Analysis: Ratings and Target Prices for Biotech Companies (Table)>

Sep 22 2025aastocks

M Stanley: Rising Recognition Drives Biotech Stocks to Surpass Market Performance

Sep 22 2025aastocks

G Sachs Provides ST Risk Assessment for Three Firm Types as US Expected to Increase Scrutiny on CN Innovative Drugs, Potentially Creating 'Headline Risks' for CN Pharmaceutical Companies

Sep 11 2025aastocks

ZAI LAB Shares Drop Approximately 13% Amid High Trading Volume Following Amgen's Final Analysis of Bemarituzumab Revealing Reduced Survival Benefit

Sep 04 2025aastocks

<Research>CCBI: Healthcare & Biotech Sectors Highly Valued, but Sector Drivers Remain Strong

Aug 14 2025aastocks

<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land

Aug 13 2025aastocks